A couple of questions / comments to the group. It appears that Amarin is well positioned with regard to the cert and the upcoming oral arguments after their well laid out response to the SC. They state in their response that only Hikma actively induced infringement. I understand that position and agree while at the same time know that all the generics have been infringing. Only Hikma took the active steps in marketing and their website to go after Amarin's CVD space. So a question is Hikma still on the hook for all lost revenue (profit) damages for their and other generics based on the infringement, or just the portion that Hikma infringed on. Seems to me they still have the same exposure for the entirety of the damages as the other generics were not part of the infringement case and before this reponse to SC they could / should have been held accountable for the entire damages from all generics.
Market Data 
Markets 
AI
